Etzer Darout
Stock Analyst at Barclays
(3.16)
# 1,202
Out of 4,996 analysts
119
Total ratings
44.09%
Success rate
2.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $45 → $44 | $38.75 | +13.55% | 6 | Sep 24, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $8 → $10 | $2.23 | +348.43% | 5 | Sep 23, 2025 | |
| XNCR Xencor | Assumes: Underweight | $6 | $11.57 | -48.14% | 6 | Sep 17, 2025 | |
| MGNX MacroGenics | Assumes: Overweight | $3 | $1.73 | +73.41% | 10 | Sep 17, 2025 | |
| EXEL Exelixis | Initiates: Equal-Weight | $40 | $39.04 | +2.46% | 4 | Sep 17, 2025 | |
| CTMX CytomX Therapeutics | Assumes: Overweight | $3.5 | $2.90 | +20.69% | 11 | Sep 17, 2025 | |
| ARVN Arvinas | Assumes: Overweight | $16 | $8.27 | +93.47% | 5 | Sep 17, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Overweight | $15 | $7.64 | +96.34% | 6 | Sep 17, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underweight | $13 | $20.95 | -37.95% | 1 | Sep 17, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | $72 | $67.42 | +6.79% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $112 | $68.89 | +62.58% | 7 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $56.25 | +6.67% | 2 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $47 | $23.23 | +102.32% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.05 | +114.88% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $98.08 | +45.80% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $1.89 | +58.73% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $47.74 | +4.73% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $8.93 | +291.94% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.47 | +2,450.61% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.66 | +1,526.51% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $81.39 | +64.64% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $29.07 | +65.12% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $123.65 | -2.95% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.00 | +500.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $73.76 | +11.17% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.86 | +290.95% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $446.40 | -61.92% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $47.74 | +13.11% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $72.76 | -47.77% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.99 | +2,513.07% | 1 | Mar 28, 2018 |
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $38.75
Upside: +13.55%
C4 Therapeutics
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.23
Upside: +348.43%
Xencor
Sep 17, 2025
Assumes: Underweight
Price Target: $6
Current: $11.57
Upside: -48.14%
MacroGenics
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.73
Upside: +73.41%
Exelixis
Sep 17, 2025
Initiates: Equal-Weight
Price Target: $40
Current: $39.04
Upside: +2.46%
CytomX Therapeutics
Sep 17, 2025
Assumes: Overweight
Price Target: $3.5
Current: $2.90
Upside: +20.69%
Arvinas
Sep 17, 2025
Assumes: Overweight
Price Target: $16
Current: $8.27
Upside: +93.47%
Terns Pharmaceuticals
Sep 17, 2025
Initiates: Overweight
Price Target: $15
Current: $7.64
Upside: +96.34%
Summit Therapeutics
Sep 17, 2025
Initiates: Underweight
Price Target: $13
Current: $20.95
Upside: -37.95%
Protagonist Therapeutics
Sep 17, 2025
Initiates: Overweight
Price Target: $72
Current: $67.42
Upside: +6.79%
Sep 17, 2025
Initiates: Overweight
Price Target: $112
Current: $68.89
Upside: +62.58%
Sep 17, 2025
Initiates: Overweight
Price Target: $60
Current: $56.25
Upside: +6.67%
Sep 17, 2025
Initiates: Overweight
Price Target: $47
Current: $23.23
Upside: +102.32%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.05
Upside: +114.88%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $98.08
Upside: +45.80%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.89
Upside: +58.73%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $47.74
Upside: +4.73%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $8.93
Upside: +291.94%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.47
Upside: +2,450.61%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.66
Upside: +1,526.51%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $81.39
Upside: +64.64%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $29.07
Upside: +65.12%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $123.65
Upside: -2.95%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.00
Upside: +500.00%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $73.76
Upside: +11.17%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.86
Upside: +290.95%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $446.40
Upside: -61.92%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $47.74
Upside: +13.11%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $72.76
Upside: -47.77%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.99
Upside: +2,513.07%